ARCHIVES

Phase II Elotuzumab Study Demonstrates 33 Months PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Malone Retires As NIH Deputy, Raub To Succeed Him

August 22, 1986

Pitt Inquiry Panel Proceedings Suspended, ORI To Take Over NSABP Investigation

July 22, 1994

Watson Steps Down As Chancellor at Cold Spring Harbor Laboratory.

October 26, 2007

In Brief: Adjuvant Chemotherapy Standard Practice For Breast Cancer At Milan, Bonadonna Says

May 7, 1976

Community Based Control Program Taking Final Shape

April 29, 1977

DCBD Board Approved Concepts For New Grants In Cytogenetics Solid Tumor Diagnoses

December 13, 1984